search
Back to results

Remote Study of NightWare for PTSD With Nightmares (NWVRCT)

Primary Purpose

PostTraumatic Stress Disorder, Sleep Disorder, Stress Disorder

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
NightWare Therapeutic System
NightWare Therapeutic System in Sham Mode
Sponsored by
NightWare
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for PostTraumatic Stress Disorder focused on measuring PTSD, Nightmare Disorder, Post-traumatic stress disorder, Veteran, Digital therapeutic, Digital medicine, Nightmares

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

  • Self report of diagnosis with PTSD
  • Self-report of PTSD-related repetitive nightmares contributing to disrupted sleep.
  • Equal to or older than 18 years of age.
  • Proficient in both reading and writing in the English language.
  • Pittsburgh Sleep Quality Index (PSQI) score equal to or greater than 10.
  • ESS: On question #8 any score above "0" will prompt an additional question:
  • Do you drive ("get behind the wheel") when you are drowsy? Answer must be "No" to be enrolled in the study for safety.
  • Participant owns or has access to devices appropriate for participation in the study including compatible Apple Watch and Apple iPhone.
  • Wireless Internet and two power outlets where they sleep.
  • Willingness not to use any other application which collects heart rate data on the phone and watch that is used for NightWare.

Exclusion Criteria

  • Circadian rhythm disruption on a regular basis (shift-work)
  • Concurrent presence of prohibited medications
  • Current use of varenicline
  • Current use of beta-blockers (unless ophthalmic solutions)
  • Current use of non-dihydropyridines
  • Current use of Prazosin for the treatment of nightmares (can include subjects 2 weeks post-taper and discontinuation)
  • Concurrent presence of prohibited diagnoses
  • Known diagnosis of OSA
  • Diagnosis of an active disorder of arousal from non-rapid eye movement sleep
  • Diagnosis of rapid eye movement sleep behavior disorder
  • Diagnosis of narcolepsy
  • Diagnosis of dementia
  • Uncontrolled atrial fibrillation
  • Use of Alcohol or Drugs as specified:
  • Alcohol Use Disorders Inventory Test (AUDIT) (score of 8 or higher)
  • Drug Abuse Screening Test-10 (DAST-10) (score greater than 2)
  • Suspicion of nightmares being secondary to substance abuse or withdrawal
  • Previous or foreseeable legal proceedings involving nightmares or trauma
  • Nocturia that causes awakening from sleep
  • Known sleep walking
  • Acting out of dreams PRIOR to PTSD trauma
  • Self reported pregnancy or intent to become pregnant during the course of the study

Sites / Locations

  • RationalPsych

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Active Treatment Arm

Sham Arm

Arm Description

Intervention with the NightWare Therapeutic System every night.

NightWare Therapeutic System every night with interventions not-enabled.

Outcomes

Primary Outcome Measures

Change in global score on the Pittsburgh Sleep Quality Index (PSQI) from Day 0 to each subsequent 28 day evaluation period
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score. In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality. This outcome is the difference between the global score on the Pittsburgh Sleep Quality Index (PSQI) score at baseline (Day 0) and average global PSQI score across the post-treatment initiation assessments (Days 14, 28 and every 28 days after that).

Secondary Outcome Measures

Full Information

First Posted
April 29, 2019
Last Updated
January 27, 2022
Sponsor
NightWare
Collaborators
RationalPsych, Center for International Emergency Medical Services
search

1. Study Identification

Unique Protocol Identification Number
NCT03934658
Brief Title
Remote Study of NightWare for PTSD With Nightmares
Acronym
NWVRCT
Official Title
A Remote Randomized Double-Blind Sham-Controlled Clinical Trial of NightWare in Adults With Post-Traumatic Stress Disorder and Co-Morbid Nightmare Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
May 21, 2019 (Actual)
Primary Completion Date
December 15, 2021 (Actual)
Study Completion Date
December 15, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NightWare
Collaborators
RationalPsych, Center for International Emergency Medical Services

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will provide measures of safety and efficacy of the NightWare digital therapeutic system (iPhone + Apple watch + proprietary application) for the treatment of nightmare disorder associated with post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with the NightWare digital therapeutic system. The investigators hypothesize that the NightWare digital therapeutic system will significantly improve sleep quality in participants with PTSD-Related nightmares and poor sleep quality.
Detailed Description
Nightmares are a common problem affecting 2-8% of the general population and a higher proportion of clinical populations. The negative consequences of untreated nightmares are significant and include impaired quality of life, sleep deprivation (often resulting in an increased intensity of nightmares), insomnia, daytime sleepiness, and fatigue. Untreated nightmares can also exacerbate the symptoms of underlying psychological dysfunction in people with depression and anxiety, leading to poor occupational and or social functioning. Nightmares can be idiopathic or associated with the use (or withdrawal) of certain medications or substances or associated with disorders including PTSD. NightWare (Minneapolis, MN) has developed a novel approach to the treatment of nightmares. Through the use of a smartwatch-based application that senses physiologic parameters, the participant is aroused from sleep (without awakening the participant) so that the nightmare is interrupted prior to reaching a threshold of severity in which the participant would awaken in distress. Seconds later the participant returns to sleep without having experienced a nightmare. This approach avoids risk from pharmacological treatment, avoids exacerbation of symptoms from image rehearsal therapy and allows for a simple method with easily achieved adherence compared to existing treatments. The NightWare digital therapeutic system consists of a proprietary software application installed on a smartwatch. The application has been effective in focus groups when used on both Apple smartwatches and Motorola smartwatches. For the purposes of this study, the investigators will be using only the Apple (Cupertino, CA) 3rd generation smartwatch and the Apple iPhone. The NightWare application uses physiological markers obtained via the smartwatch to determine by proprietary algorithm whether a participant is in the early stages of a nightmare, but has not yet awoken in distress. As directed by the algorithm, the smartwatch then applies varying degrees of vibratory stimulation to the wrist over variable lengths of time with the intention of arousing the participant from sleep without eliciting an awakening.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PostTraumatic Stress Disorder, Sleep Disorder, Stress Disorder, Sleep Initiation and Maintenance Disorders, Combat Disorders, Nightmares Associated With Chronic Post-Traumatic Stress Disorder, Nightmare, Nightmares, REM-Sleep Type
Keywords
PTSD, Nightmare Disorder, Post-traumatic stress disorder, Veteran, Digital therapeutic, Digital medicine, Nightmares

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
81 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Active Treatment Arm
Arm Type
Experimental
Arm Description
Intervention with the NightWare Therapeutic System every night.
Arm Title
Sham Arm
Arm Type
Sham Comparator
Arm Description
NightWare Therapeutic System every night with interventions not-enabled.
Intervention Type
Device
Intervention Name(s)
NightWare Therapeutic System
Intervention Description
A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
Intervention Type
Device
Intervention Name(s)
NightWare Therapeutic System in Sham Mode
Intervention Description
A wearable digital therapeutic system that will measure physiologic data when worn during sleep that does not deliver interventions.
Primary Outcome Measure Information:
Title
Change in global score on the Pittsburgh Sleep Quality Index (PSQI) from Day 0 to each subsequent 28 day evaluation period
Description
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score. In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality. This outcome is the difference between the global score on the Pittsburgh Sleep Quality Index (PSQI) score at baseline (Day 0) and average global PSQI score across the post-treatment initiation assessments (Days 14, 28 and every 28 days after that).
Time Frame
0-730 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Self report of diagnosis with PTSD Self-report of PTSD-related repetitive nightmares contributing to disrupted sleep. Equal to or older than 18 years of age. Proficient in both reading and writing in the English language. Pittsburgh Sleep Quality Index (PSQI) score equal to or greater than 10. ESS: On question #8 any score above "0" will prompt an additional question: Do you drive ("get behind the wheel") when you are drowsy? Answer must be "No" to be enrolled in the study for safety. Participant owns or has access to devices appropriate for participation in the study including compatible Apple Watch and Apple iPhone. Wireless Internet and two power outlets where they sleep. Willingness not to use any other application which collects heart rate data on the phone and watch that is used for NightWare. Exclusion Criteria Circadian rhythm disruption on a regular basis (shift-work) Concurrent presence of prohibited medications Current use of varenicline Current use of beta-blockers (unless ophthalmic solutions) Current use of non-dihydropyridines Current use of Prazosin for the treatment of nightmares (can include subjects 2 weeks post-taper and discontinuation) Concurrent presence of prohibited diagnoses Known diagnosis of OSA Diagnosis of an active disorder of arousal from non-rapid eye movement sleep Diagnosis of rapid eye movement sleep behavior disorder Diagnosis of narcolepsy Diagnosis of dementia Uncontrolled atrial fibrillation Use of Alcohol or Drugs as specified: Alcohol Use Disorders Inventory Test (AUDIT) (score of 8 or higher) Drug Abuse Screening Test-10 (DAST-10) (score greater than 2) Suspicion of nightmares being secondary to substance abuse or withdrawal Previous or foreseeable legal proceedings involving nightmares or trauma Nocturia that causes awakening from sleep Known sleep walking Acting out of dreams PRIOR to PTSD trauma Self reported pregnancy or intent to become pregnant during the course of the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel R Karlin, MD MA
Organizational Affiliation
RationalPsych
Official's Role
Principal Investigator
Facility Information:
Facility Name
RationalPsych
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

Remote Study of NightWare for PTSD With Nightmares

We'll reach out to this number within 24 hrs